Kardigan filed for an IPO in the United States to fund development of three late-stage cardiovascular therapies. The filing follows recent IPO moves by Parabilis Medicines and Oura amid a rebound in biotech issuance. Investors are returning to healthcare firms with clear paths toward commercialization.

Funding Three Late-Stage Heart Therapies